Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (Diluted Average) (2016 - 2025)

Cytosorbents (CTSO) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $62.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 13.93% year-over-year to $62.0 million, compared with a TTM value of $62.0 million through Sep 2025, up 13.93%, and an annual FY2024 reading of $54.4 million, up 21.9% over the prior year.
  • Shares Outstanding (Diluted Average) was $62.0 million for Q3 2025 at Cytosorbents, down from $66.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $66.3 million in Q2 2025 and bottomed at $43.3 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $49.0 million, with a median of $44.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 0.36% in 2022, then increased 24.63% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $43.4 million in 2021, then increased by 0.49% to $43.6 million in 2022, then rose by 2.49% to $44.7 million in 2023, then rose by 21.9% to $54.4 million in 2024, then grew by 13.97% to $62.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CTSO at $62.0 million in Q3 2025, $66.3 million in Q2 2025, and $60.7 million in Q1 2025.